Stay updated on TACTIVE-U Study of ARV-471 Combo in Adv Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the TACTIVE-U Study of ARV-471 Combo in Adv Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TACTIVE-U Study of ARV-471 Combo in Adv Breast Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The value (Estimated) on the webpage has recently changed to . This change likely indicates an update in the estimated completion date for the clinical trial related to the study medicine ARV-471 in combination with ribociclib for the treatment of advanced or metastatic breast cancer.
    Difference
    0.0%
    Check dated 2024-05-07T20:08:29.000Z thumbnail image
  7. Check
    12 days ago
    Change Detected
    Summary
    The value 04 05 28 28 04 04 04 05 04 has been updated to 05 06 14 14 in the webpage, indicating a change in location details from Tampa, Florida, United States, 33607 Not yet recruiting Moffitt Cancer Center - International Plaza to Barcelona, Barcelona [barcelona], Spain, 08035 Recruiting Hospital Universitari Vall d'Hebron. This change likely reflects a shift in the recruitment status and location of a medical study related to breast cancer treatment.
    Difference
    2%
    Check dated 2024-05-06T17:53:34.000Z thumbnail image
  8. Check
    18 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:43:32.000Z thumbnail image

Stay in the know with updates to TACTIVE-U Study of ARV-471 Combo in Adv Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TACTIVE-U Study of ARV-471 Combo in Adv Breast Cancer Clinical Trial page.